In clinical studies, immune checkpoint inhibitors targeting PD-1/PD-L1 applied as single treatment regime reached response rates of 4.7 to 23.1% of patients of metastasized breast cancer dependent of subtype and PD-L1 expression. Here, PDCD1 is linked to breast cancer.